{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:03:45Z","timestamp":1789499025150,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th quarter of 2024. For signal quantification of dextromethorphan-bupropion-related AEs, we used disproportionality methods including the reporting odds ratio, proportional reporting ratio, and multi-item gamma Poisson shrinker algorithms. Our study analyzed 4,804,129 AEs, while 3580 AEs were associated with dextromethorphan-bupropion, which included 266 preferred term signals and 21 system organ classes. These AEs mainly occurred as psychiatric disorders (21.17%), nervous system disorders (20.92%), general disorders, administration site conditions (19.75%), and others. Notably, obsessive rumination (n\u2005=\u20053, reporting odds ratio\u2005=\u2005366.02, proportional reporting ratio\u2005=\u2005365.71, empirical Bayes geometric mean\u2005=\u2005287.56) exhibited the lowest morbidity, whereas the highest signal intensity. Specifically, 65.3% of preferred terms were not explicitly mentioned in the instructions, which suggested the previously unlabeled signals. Dextromethorphan-bupropion poses potential reporting signals of various AEs, though providing therapeutic effects. In clinical applications, practitioners should closely monitor occurrences of psychiatric disorders, nervous system disorders, general disorders, administration site conditions, and other events. Meanwhile, professional clinicians should be alerted to the AEs signals not mentioned in the label to secure clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049464","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:02:34Z","timestamp":1782496954000},"page":"e49464","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6947-9509","authenticated-orcid":false,"given":"Ruixue","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cangzhou People\u2019s Hospital, Cangzhou, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longkun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Anding Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","first-page":"425","article-title":"Study to determine the epidemiology of treatment-resistant depression among the Saudi Arabian population: a cross-sectional study.","volume":"12","author":"Alshehri","year":"2023","journal-title":"J Educ Health Promot"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"115958","DOI":"10.1016\/j.psychres.2024.115958","article-title":"Global, regional, and national temporal trend in burden of major depressive disorder from 1990 to 2019: an analysis of the global burden of disease study.","volume":"337","author":"Yan","year":"2024","journal-title":"Psychiatry Res"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression.","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"21r14328","DOI":"10.4088\/JCP.21r14328","article-title":"Impact of major depressive disorder on comorbidities: a systematic literature review.","volume":"83","author":"Arnaud","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpsychires.2021.02.053","article-title":"Estimating the risk of suicide associated with mental disorders: a systematic review and meta-regression analysis.","volume":"137","author":"Moitra","year":"2021","journal-title":"J Psychiatr Res"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1007\/s12325-023-02622-x","article-title":"The economic burden of adults with major depressive disorder in the United States (2019).","volume":"40","author":"Greenberg","year":"2023","journal-title":"Adv Ther"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis.","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Psychiatry"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"106837","DOI":"10.1016\/j.phrs.2023.106837","article-title":"Molecular mechanisms of rapid-acting antidepressants: new perspectives for developing antidepressants.","volume":"194","author":"Chen","year":"2023","journal-title":"Pharmacol Res"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.phrs.2018.10.025","article-title":"The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications.","volume":"139","author":"Fornaro","year":"2019","journal-title":"Pharmacol Res"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","article-title":"Glutamatergic modulators for major depression from theory to clinical use.","volume":"38","author":"McIntyre","year":"2024","journal-title":"CNS Drugs"},{"key":"R12-20260915","first-page":"104629","article-title":"Rapid-acting oral drug (Auvelity) for major depressive disorder.","volume":"82","author":"Khabir","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"21m14345","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI).","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1002\/pcn5.157","article-title":"Emerging trends in antipsychotic and antidepressant drug development: targeting nonmonoamine receptors and innovative mechanisms.","volume":"2","author":"Osaka","year":"2023","journal-title":"PCN Rep"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"925879","DOI":"10.3389\/fphar.2022.925879","article-title":"Sigma-1 receptors in depression: mechanism and therapeutic development.","volume":"13","author":"Ren","year":"2022","journal-title":"Front Pharmacol"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1017\/S1092852919001470","article-title":"Dextromethorphan\/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity.","volume":"24","author":"Stahl","year":"2019","journal-title":"CNS Spectr"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database.","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"1414703","DOI":"10.3389\/fphar.2024.1414703","article-title":"Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1745-6924.2008.00088.x","article-title":"Rethinking rumination.","volume":"3","author":"Nolen-Hoeksema","year":"2008","journal-title":"Perspect Psychol Sci"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jbtep.2019.02.006","article-title":"Is repetitive negative thinking a transdiagnostic process? A comparison of key processes of RNT in depression, generalized anxiety disorder, obsessive-compulsive disorder, and community controls.","volume":"64","author":"Wahl","year":"2019","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1192\/j.eurpsy.2022.1051","article-title":"A case of ruminative hypomania induced by high dose venlafaxine.","volume":"65","author":"Yildizhan","year":"2022","journal-title":"Eur Psychiatry"},{"key":"R25-20260915","year":"2022","journal-title":"Diagnostic and statistical manual of mental disorders: DSM-5-TR (5th edition, text revision.)"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2004.08.006","article-title":"Are there two qualitatively distinct forms of dissociation? A review and some clinical implications.","volume":"25","author":"Holmes","year":"2005","journal-title":"Clin Psychol Rev"},{"key":"R27-20260915","year":"2019","journal-title":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder"},{"key":"R28-20260915","year":"2020","journal-title":"Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications"},{"key":"R29-20260915","first-page":"123","article-title":"Antipsychotic drugs efficacy in dextromethorphan-induced psychosis.","volume":"11","author":"Zaremba","year":"2023","journal-title":"Biomed"},{"key":"R30-20260915","first-page":"722","article-title":"Management of sexual side effects of antidepressants.","volume":"77","author":"Deprez","year":"2022","journal-title":"Rev Med Liege"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14740338.2022.2049753","article-title":"Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management.","volume":"21","author":"Winter","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial.","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am J Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:11:23Z","timestamp":1789495883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":29,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049464","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2025-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}